Simultaneously Manufactured Nano-In-Micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies

Journal of Pharmaceutical Sciences

Volumn 98, Issue 11, 2009, Pages 4055-4068

  Kaye, Richard S ^a   Purewal, Tol S ^b   Alpar, H Oya ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b Bespak Plc   (United Kingdom)

Author keywords

Aerosol; Antibody; Inhaled; Microparticles; Nanoparticles; Poly(lactic glycolic) acid (PLGA); Protein delivery; Pulmonary drug delivery; Spray drying

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LACTOSE; LEUCINE; MAGNESIUM STEARATE; NANOPARTICLE; POLYGLACTIN;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIELD FLOW FRACTIONATION; GEL ELECTROPHORESIS; INHALER; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

EID: 70349651190     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21673     Document Type: Article

References (34)

1. Bilati U, Allemann E, Doelker E. 2005. Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur J Pharm Biopharm 59:375-388. (Pubitemid 40342512)
2. Freiberg S, Zhu XX. 2004. Polymer microspheres for controlled drug release. Int J Pharm 282:1-18. (Pubitemid 39178480)
3. Grenha A, Seijo B, Remunan-Lopez C. 2005. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci 25:427-437. (Pubitemid 40853870)
4. Evora C, Soriano I, Rogers RA, Shakesheff KM, Hanes J, Langer R. 1998. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: The effect of 1,2-dipalmitoylphosphatidylcholine. J Control Release 51:143-152. (Pubitemid 28252865)
5. Fraunhofer W, Winter G. 2004. The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics. Eur J Pharm Biopharm 58:369-383. (Pubitemid 39037242)
6. European Pharmacopoeia 5 2005. Preparations for inhalation: Aerodynamic assessment of fine particles, apparatus D - "Andersen" sizing sampler 1: pp 250-253.
7. US Pharmacopoeia 29 2006. 〈601〉 Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers - particle size, pp 2622-2636.
8. Criée CP, Meyer T, Petro W, Sommerer K, Zeising P. 2006. In vitro comparison of two delivery devices for administering formoterol: Foradil® P and formoterol Ratiopharm single-dose capsule inhaler. J Aerosol Med 19:466-472.
9. Learoyd TP, Burrows JL, French E, Seville PC. 2008. Chitosan-based spray-dried respirable powders for sustained delivery of terbutaline sulfate. Eur J Pharm Biopharm 68:224-234.
10. Seville PC, Learoyd TP, Li HY, Williamson IJ, Birchall JC. 2007. Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol 178:40-50.
11. Dellamary L, Smith DJ, Bloom A, Bot S, Guo G-R, Deshmuk H, Costello M, Bot A. 2004. Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics. J Control Release 95:489-500. (Pubitemid 38340499)
12. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. 2002. Trojan particles: Large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 99:12001-12005.
13. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. 2007. Nanoparticles: Pharmacological and toxicological significance. Br J Pharm 150:552-558.
14. Takashima Y, Saito R, Nakajima A, Oda M, Kimura A, Kanazawa T, Okada H. 2007. Spray-drying preparation of microparticles containing cationic PLGA nanospheres as gene carriers for avoiding aggregation of nanospheres. Int J Pharm 343:262-269. (Pubitemid 47321027)
15. Tamber H, Johansen P, Merkle H, Gander B. 2005. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev 57:357-376. (Pubitemid 39555502)
16. Witschi C, Doelker E. 1998. Influence of the microencapsulation method and peptide loading on poly-(lactic acid) and poly(lactic-co-glycolic acid) degradation during in vivo testing. J Control Release 51:327-341. (Pubitemid 28252884)
17. Jiang G, Woo BH, Kang F, Singh J, DeLuca PE. 2002. Assessment of protein release kinetics, stability and protein polymer interaction of lysozyme encapsulated poly(D,L-lactide-co-glycolide) microspheres. J Control Release 79:137-145. (Pubitemid 34164167)
18. Schwendeman SP. 2002. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carrier Syst 19:73-98.
19. Zheng JY, Janis LJ. 2006. Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. Int J Pharm 308:46-51.
20. Giteaua A, Venier-Juliennea MC, Aubert-Pouësselc A, Benoita JP. 2008. How to achieve sustained and complete protein release from PLGA-based microparticles? Int J Pharm 350:14-26.
21. Pollit MJ. 2006. Protein coating of nanoparticles. PhD Thesis, School of Pharmacy, University of London.
22. Gabrielson JP, Brader ML, Pekar AH, Mathis KB, Winter G, Carpenter JF, Randolph TW. 2007. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci 96:268-279. (Pubitemid 46363558)
23. Hickey AJ, Concessio NM, Van Oort MM, Platz RM. 1994. Factors influencing the dispersion of dry powders as aerosols. Pharm Tech 18:58-64.
24. Kippax P. 2005. Issues in the appraisal of laser diffraction particle sizing techniques. Pharm Technol Eur: 32-39. (Pubitemid 40109559)
25. Snell NJC. 1997. Assessing equivalence of inhaled products. J Pharm Pharmacol 49:55-60.
26. Lucas P, Anderson K, Potter UJ, Staniforth JN. 1999. Enhancement of small particle size dry powder aerosol formulations using ultra low density additive. Pharm Res 16:1643-1647. (Pubitemid 29510566)
27. Staniforth JN. 2002. Powders comprising anti-adherant materials for use in dry powder inhalers. USA Patent 6,475,523, Vectura Ltd.
28. Najafabadi AR, Gilani K, Barghi M, Rafiee-Tehrani M. 2004. The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray-dried alone or with L-leucine. Int J Pharm 285:97-108. (Pubitemid 39361540)
29. Rabbani NR, Seville PC. 2005. The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Release 110:130-140.
30. Weers JG, Tarara TE, Clark AR. 2007. Design of fine particles for pulmonary drug delivery. Expert Opin Drug Deliv 4:297-313. (Pubitemid 46772848)
31. Fineberg SE, Kawabata TT, Krasner AS, Fineberg NS. 2007. Insulin antibodies with pulmonary delivery of insulin. Diabetes Technol Ther 9:S102-S110.
32. Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble KR, Clark AR, Eldon MA, Elton RC, Pickford M, Hirst PH, Newman SP, Weers JG. 2002. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere® powder. Pharm Res 19:689-695. (Pubitemid 34553679)
33. Bosquillon C, Rouxhet PG, Ahimou F, Simon D, Culot C, Preat V, Vanbever R. 2004. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J Control Release 99:357-367. (Pubitemid 39296905)
34. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. 1997. Large porous particles for pulmonary drug delivery. Science 276:1868-1871. (Pubitemid 27443665)